Main Content start here
Main Layout
Report Description

Report Description

The global venom-based drugs market is anticipated to observe impressive growth during the forecast period, 2023-2027. The major factors include growing incidences of various diseases, and rise in initiatives by government and private organizations, which are curbing the growth of the market. Venom is a compound which is secreted by an animal. It is a poisonous compound which intended to harm or disable their prey or enemy. When venom is produced through organisms, it includes variety of bioactive components which produce toxic effects. Only those active components of these venoms are isolated, purified, and screened which may have desirable therapeutic properties. The other factors supporting the market’s growth are, the extensive research and development, large number of clinical trials, increasing awareness, and government investments, large number of venomous animals, ease in approval of new venom-based drugs, and technological advancements in this field.

Increasing Use of Venom in Numerous Diseases

Venom derived drugs are very useful in treating various diseases such as cancer, heart attack, hypertension, acute coronary syndrome, and other, due to their potential therapeutic values, which propels the growth of the market. Several venom-based drugs are already in use such as captopril, integrilin, reptilase, exanta and others. Moreover, these venom-based drugs are used as diagnostic tools, cosmeceuticals and for drug discovery. For instance, in 2020, a study concluded that bee venom therapy might be useful in treating inflammatory forms of arthritis. Similarly, captopril is a type of drug used to cure high blood pressure and reduce the risk of heart failure after a heart attack. It is derived from a species of pit viper which is found in Brazil.

Technological Advancements and Rise in R&D activities

Owing to rising number of patients suffering from variety of diseases, the surge in demand for the treatment, is augmenting the growth of the market, globally. Various R&D activities are carried by researchers in order to treat these diseases using venom from various animals. The toxins from venom such as proteins, peptides, carbohydrates, and other components are important research tools. Subsequently, other reasons that make animal venoms attractive to researchers across the globe are the specialization, richness, and efficiency of the components present. Also, advancement in genomics, transcriptions and proteomics helps in study of these toxins, which further aids scientists to understand the venoms and their target. For instance, tozuleristide, a diagnostic drug obtained from the venom of the Israeli deathstalker scorpion, is now in clinical trials. An element of the venom, called chlorotoxin, binds to tumor cells. Researchers at the Fred Hutchinson Cancer Research Center re-engineered this protein and attached a fluorescent tag to it, resulting in a diagnostic tool that seeks out and illuminates tumors.


Download Free Sample Report

Market Segmentation

The global venom-based drugs market is segmented into animal type, source, therapeutic area, and company. Based on animal type, the market is divided into snake, spider, bee, and others. Based on source, the market is divided into whole venom, synthetic, recombinant, and others. Based on therapeutic area, the market is segmented into hypertension, cardiovascular diseases, neurological disorders, pain management & arthritis, and others. In terms of country, the United States is expected to be a lucrative market in the forecast period due to extensive research and development on venom based drugs in the country.

Market Players

AstraZeneca Plc., Bristol-Myers Squibb Company, Merck & Co., Inc., Pentapharm Limited Medicure Inc, Millennium Pharmaceuticals, Inc., Bausch Health Companies, Inc., Novartis AG, Elan Pharmaceuticals, Inc., and Beijing Tobishi Pharmaceutical Co., Ltd. are some of the leading companies operating in the market.

Attribute

Details

Base Year

2021

Historic Data

2017 – 2020

Estimated Year

2022

Forecast Period

2023 – 2027

Quantitative Units

Revenue in USD Million, Volume Units and CAGR for 2017-2021 and 2022-2027

Report coverage

Revenue forecast, Volume forecast company share, competitive landscape, growth factors, and trends

Segments covered

·         Animal Type

·         Source

·         Therapeutic Area

·         Company

Regional scope

North America; Asia Pacific; Europe & CIS; South America; Middle East & Africa

Country scope

United States; Canada; Mexico; China; India; Japan; South Korea; Germany; France; United Kingdom; Spain; Italy; Brazil; Argentina; Colombia; South Africa; UAE; Saudi Arabia; South Africa

Key companies profiled

AstraZeneca Plc., Bristol-Myers Squibb Company, Merck & Co., Inc., Pentapharm Limited Medicure Inc, Millennium Pharmaceuticals, Inc., Bausch Health Companies, Inc., Novartis AG, Elan Pharmaceuticals, Inc., and Beijing Tobishi Pharmaceutical Co., Ltd.

Customization scope

10% free report customization with purchase. Addition or alteration to country, regional & segment scope.

Pricing and purchase options

Avail customized purchase options to meet your exact research needs. Explore purchase options

Delivery Format

PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)


Report Scope:

In this report, global venom based drugs market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

·         Venom Based Drugs Market, By Animal Type:

    • Snake
    • Spider
    • Bee
    • Others    

·         Venom Based Drugs Market, By Source:

    • Whole Venom
    • Synthetic
    • Recombinant
    • Others

·         Venom Based Drugs Market, By Therapeutic Area:

    • Hypertension
    • Cardiovascular Diseases
    • Neurological Disorders
    • Pain Management & Arthritis
    • Others

·         Venom Based Drugs Market, By Region:

    • North America
      • United States
      • Canada
      • Mexico
    • Asia-Pacific
      • China
      • India
      • Japan
      • Australia
      • South Korea
    • Europe & CIS
      • Germany
      • France
      • United Kingdom
      • Spain
      • Italy
    • South America
      • Brazil
      • Argentina
      • Colombia
    • Middle East & Africa

o   South Africa

o   Saudi Arabia

o   UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in Venom Based Drugs Market

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company’s specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).
Venom Based Drugs Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]
Table of content

Table of content

1.    Product Overview

2.    Research Methodology

3.    Impact of COVID-19 on Global Venom Based Drugs Market

4.    Executive Summary

5.    Voice of Customer

5.1.  Benefits of Using Venom Based Drugs

5.2.  Commonly Used Animals for Deriving Venom Based Drugs

5.3.  Demand for Venom Based Drugs, By Therapeutic Area

5.4.  Barriers to Adoption of Venom Based Drugs

6.    List of Venom Based Approved Drugs by the FDA

7.    Clinical Trials Analysis

8.    Global Venom Based Drugs Market Outlook

8.1.  Market Size & Forecast

8.1.1.     By Value

8.2.  Market Share & Forecast

8.2.1.     By Animal Type (Snake, Spider, Bee, Others)

8.2.2.     By Source (Whole Venom, Synthetic, Recombinant, Others)

8.2.3.     By Therapeutic Area (Hypertension, Cardiovascular Diseases, Neurological Disorders, Pain Management & Arthritis, Others)

8.2.4.     By Company (2021)

8.2.5.     By Region

8.3.  Market Map

9.    North America Venom Based Drugs Market Outlook

9.1.  Market Size & Forecast          

9.1.1.     By Value

9.2.  Market Share & Forecast

9.2.1.     By Animal Type

9.2.2.     By Source

9.2.3.     By Therapeutic Area

9.2.4.     By Country

9.3.  North America: Country Analysis

9.3.1.     United States Venom Based Drugs Market Outlook

9.3.1.1.         Market Size & Forecast

9.3.1.1.1.             By Value

9.3.1.2.         Market Share & Forecast

9.3.1.2.1.             By Animal Type

9.3.1.2.2.             By Source

9.3.1.2.3.             By Therapeutic Area

9.3.2.     Mexico Venom Based Drugs Market Outlook

9.3.2.1.         Market Size & Forecast

9.3.2.1.1.             By Value

9.3.2.2.         Market Share & Forecast

9.3.2.2.1.             By Animal Type

9.3.2.2.2.             By Source

9.3.2.2.3.             By Therapeutic Area

9.3.3.     Canada Venom Based Drugs Market Outlook

9.3.3.1.         Market Size & Forecast

9.3.3.1.1.             By Value

9.3.3.2.         Market Share & Forecast

9.3.3.2.1.             By Animal Type

9.3.3.2.2.             By Source

9.3.3.2.3.             By Therapeutic Area

10.  Europe Venom Based Drugs Market Outlook

10.1.              Market Size & Forecast

10.1.1.  By Value

10.2.              Market Share & Forecast

10.2.1.  By Animal Type

10.2.2.  By Source

10.2.3.  By Therapeutic Area

10.2.4.  By Country

10.3.              Europe: Country Analysis

10.3.1.  France Venom Based Drugs Market Outlook

10.3.1.1.      Market Size & Forecast

10.3.1.1.1.           By Value

10.3.1.2.      Market Share & Forecast

10.3.1.2.1.           By Animal Type

10.3.1.2.2.           By Source

10.3.1.2.3.           By Therapeutic Area

10.3.2.  Germany Venom Based Drugs Market Outlook

10.3.2.1.      Market Size & Forecast

10.3.2.1.1.           By Value

10.3.2.2.      Market Share & Forecast

10.3.2.2.1.           By Animal Type

10.3.2.2.2.           By Source

10.3.2.2.3.           By Therapeutic Area

10.3.3.  United Kingdom Venom Based Drugs Market Outlook

10.3.3.1.      Market Size & Forecast

10.3.3.1.1.           By Value

10.3.3.2.      Market Share & Forecast

10.3.3.2.1.           By Animal Type

10.3.3.2.2.           By Source

10.3.3.2.3.           By Therapeutic Area

10.3.4.  Italy Venom Based Drugs Market Outlook

10.3.4.1.      Market Size & Forecast

10.3.4.1.1.           By Value

10.3.4.2.      Market Share & Forecast

10.3.4.2.1.           By Animal Type

10.3.4.2.2.           By Source

10.3.4.2.3.           By Therapeutic Area

10.3.5.  Spain Venom Based Drugs Market Outlook

10.3.5.1.      Market Size & Forecast

10.3.5.1.1.           By Value

10.3.5.2.      Market Share & Forecast

10.3.5.2.1.           By Animal Type

10.3.5.2.2.           By Source

10.3.5.2.3.           By Therapeutic Area

11.  Asia-Pacific Venom Based Drugs Market Outlook

11.1.              Market Size & Forecast

11.1.1.  By Value

11.2.              Market Share & Forecast

11.2.1.  By Animal Type

11.2.2.  By Source

11.2.3.  By Therapeutic Area

11.2.4.  By Country

11.3.              Asia-Pacific: Country Analysis

11.3.1.  China Venom Based Drugs Market Outlook

11.3.1.1.      Market Size & Forecast

11.3.1.1.1.           By Value

11.3.1.2.      Market Share & Forecast

11.3.1.2.1.           By Animal Type

11.3.1.2.2.           By Source

11.3.1.2.3.           By Therapeutic Area

11.3.2.  India Venom Based Drugs Market Outlook

11.3.2.1.      Market Size & Forecast

11.3.2.1.1.           By Value

11.3.2.2.      Market Share & Forecast

11.3.2.2.1.           By Animal Type

11.3.2.2.2.           By Source

11.3.2.2.3.           By Therapeutic Area

11.3.3.  Japan Venom Based Drugs Market Outlook

11.3.3.1.      Market Size & Forecast

11.3.3.1.1.           By Value

11.3.3.2.      Market Share & Forecast

11.3.3.2.1.           By Animal Type

11.3.3.2.2.           By Source

11.3.3.2.3.           By Therapeutic Area

11.3.4.  South Korea Venom Based Drugs Market Outlook

11.3.4.1.      Market Size & Forecast

11.3.4.1.1.           By Value

11.3.4.2.      Market Share & Forecast

11.3.4.2.1.           By Animal Type

11.3.4.2.2.           By Source

11.3.4.2.3.           By Therapeutic Area

11.3.5.  Australia Venom Based Drugs Market Outlook

11.3.5.1.      Market Size & Forecast

11.3.5.1.1.           By Value

11.3.5.2.      Market Share & Forecast

11.3.5.2.1.           By Animal Type

11.3.5.2.2.           By Source

11.3.5.2.3.           By Therapeutic Area

12.  South America Venom Based Drugs Market Outlook

12.1.              Market Size & Forecast

12.1.1.  By Value

12.2.              Market Share & Forecast

12.2.1.  By Animal Type

12.2.2.  By Source

12.2.3.  By Therapeutic Area

12.2.4.  By Country

12.3.              South America: Country Analysis

12.3.1.  Brazil Venom Based Drugs Market Outlook

12.3.1.1.      Market Size & Forecast

12.3.1.1.1.           By Value

12.3.1.2.      Market Share & Forecast

12.3.1.2.1.           By Animal Type

12.3.1.2.2.           By Source

12.3.1.2.3.           By Therapeutic Area

12.3.2.  Argentina Venom Based Drugs Market Outlook

12.3.2.1.      Market Size & Forecast

12.3.2.1.1.           By Value

12.3.2.2.      Market Share & Forecast

12.3.2.2.1.           By Animal Type

12.3.2.2.2.           By Source

12.3.2.2.3.           By Therapeutic Area

12.3.3.  Colombia Venom Based Drugs Market Outlook

12.3.3.1.      Market Size & Forecast

12.3.3.1.1.           By Value

12.3.3.2.      Market Share & Forecast

12.3.3.2.1.           By Animal Type

12.3.3.2.2.           By Source

12.3.3.2.3.           By Therapeutic Area

13.  Middle East and Africa Venom Based Drugs Market Outlook

13.1.              Market Size & Forecast

13.1.1.  By Value

13.2.              Market Share & Forecast

13.2.1.  By Animal Type

13.2.2.  By Source

13.2.3.  By Therapeutic Area

13.2.4.  By Country

13.3.              MEA: Country Analysis

13.3.1.  South Africa Venom Based Drugs Market Outlook

13.3.1.1.      Market Size & Forecast

13.3.1.1.1.           By Value

13.3.1.2.      Market Share & Forecast

13.3.1.2.1.           By Animal Type

13.3.1.2.2.           By Source

13.3.1.2.3.           By Therapeutic Area

13.3.2.  Saudi Arabia Venom Based Drugs Market Outlook

13.3.2.1.      Market Size & Forecast

13.3.2.1.1.           By Value

13.3.2.2.      Market Share & Forecast

13.3.2.2.1.           By Animal Type

13.3.2.2.2.           By Source

13.3.2.2.3.           By Therapeutic Area

13.3.3.  UAE Venom Based Drugs Market Outlook

13.3.3.1.      Market Size & Forecast

13.3.3.1.1.           By Value

13.3.3.2.      Market Share & Forecast

13.3.3.2.1.           By Animal Type

13.3.3.2.2.           By Source

13.3.3.2.3.           By Therapeutic Area

14.  Market Dynamics

14.1.              Drivers

14.2.              Challenges

15.  Market Trends & Developments

16.  Competitive Landscape

16.1.              AstraZeneca Plc.

16.2.              Bristol-Myers Squibb Company

16.3.              Merck & Co., Inc.

16.4.              Pentapharm Limited

16.5.              Medicure Inc

16.6.              Millennium Pharmaceuticals, Inc.

16.7.              Bausch Health Companies, Inc.

16.8.              Novartis AG

16.9.              Elan Pharmaceuticals, Inc.

16.10.            Beijing Tobishi Pharmaceutical Co., Ltd.

17.  Strategic Recommendations

Figures and Tables

Frequently asked questions

Frequently asked questions

Growing occurrences of different types of diseases, growing awareness, and extensive research and development are driving the demand for the global venom based drugs market.

AstraZeneca Plc., Bristol-Myers Squibb Company, Merck & Co., Inc., Pentapharm Limited Medicure Inc, Millennium Pharmaceuticals, Inc., Bausch Health Companies, Inc., Novartis AG, Elan Pharmaceuticals, Inc., and Beijing Tobishi Pharmaceutical Co., Ltd. are the key players operating in the global venom based drugs market.

The drug development from animal venom is an expensive, dangerous, and often unprofitable venture which may likely hamper the growth of the global venom based drugs market.

The Global Venom Based Drugs Market is studied from 2017 to 2027.

Related Reports